GLP-1 Drug Pricing Guide: Best Prices as of June 2026
June 2026 GLP-1 pricing update: CVS Caremark Foundayo + Zepbound formulary deal, Wegovy pill UK + UAE launches, 503B sunset June 29, Medicare Bridge July 1.
The June 2026 GLP-1 pricing picture has shifted in three structurally meaningful ways since the May update.
First, CVS Caremark closed the PBM coverage gap. Effective June 1, 2026, Caremark removed the new-to-market block on Lilly's Foundayo (orforglipron). Effective October 1, 2026, Zepbound returns to commercial formularies as an additional preferred option after the mid-2025 formulary removal. With Express Scripts and OptumRx already covering both, this aligns coverage across the three major US pharmacy benefit managers and reaches roughly 25-30 million Americans on the Caremark standard formulary template. CVS officials cited a price-secure agreement with Lilly that brings out-of-pocket cost as low as $25/month for eligible commercially insured patients.
Second, Novo Nordisk's Wegovy pill went international. The Emirates Drug Establishment cleared the launch in the UAE on June 3, 2026, with Abu Dhabi and Dubai pharmacies stocking 1.5, 4, 9, and 25 mg strengths at AED 779-1,610 per month. The UK MHRA approved oral semaglutide 25 mg for chronic weight management on June 11, the third national approval after the US (January 5) and the UAE. UK private-prescription availability is expected within weeks; NHS coverage waits on a separate NICE cost-effectiveness appraisal. Wegovy pill US prescriptions have crossed 3 million in the first five months on the market.
Third, the regulatory countdown is now days, not weeks. The FDA's 503B comment window on excluding semaglutide, tirzepatide, and liraglutide from the bulks list closes June 29, 2026, 16 days from today. The Medicare GLP-1 Bridge program launches July 1 with a $50/month copay for eligible Part D beneficiaries. The PCAC peptide-compounding advisory-committee oral-presentation request deadline closes June 30, with the formal meeting scheduled for July 23-24 to weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. And Novo Nordisk's $199/month Wegovy injectable starter promotion (0.25 and 0.5 mg doses) expires June 30 as well, after which starter doses revert to the standard $349 self-pay tier.
The bottom-line price points for June 2026: commercially insured patients still pay as low as $25/mo with a savings card or PBM-covered access. Uninsured self-pay starts at $149/mo (Foundayo LillyDirect starter, Wegovy pill 1.5 mg, Wegovy pill 4 mg through August 31) and runs to $449/mo (Zepbound prefilled pens maintenance). Medicare patients pay $50/mo through the GLP-1 Bridge starting July 1. WAC list prices have not moved and remain disconnected from what patients actually pay.
For the comprehensive May baseline, see GLP-1 Pricing: May 2026. For the April detail, see GLP-1 Pricing: April 2026. For the Medicare program in detail, see Medicare GLP-1 Bridge Pricing 2026. For the Canada generic semaglutide story, see Generic Semaglutide Canada Pricing.
CVS Caremark Coverage Expansion — Foundayo June 1, Zepbound October 1
On May 28, 2026, CVS Caremark announced two coverage changes for the standard commercial formulary template, which covers roughly 25-30 million Americans. Effective June 1, 2026, the new-to-market block on Foundayo (orforglipron) was removed. Effective October 1, 2026, Zepbound returns as an additional preferred option after the mid-2025 formulary removal that had pushed patients toward Wegovy. CVS cited an agreement with Lilly that brings out-of-pocket cost as low as $25/month for eligible commercially insured patients on both drugs. The specific employer or union determines actual copay tier.
| Channel | Price | Source |
|---|---|---|
| Foundayo via CVS Caremark (Commercial) | As low as $25/mo | CVS Health |
| Zepbound via CVS Caremark (Commercial) | As low as $25/mo | Managed Healthcare Executive |
| PBM Coverage Status (All Three Major) | Foundayo + Zepbound covered by Caremark, Express Scripts, OptumRx | CNBC |
| Medicare Part D (Bridge) | $50/mo copay | CMS |
Wegovy Pill International — UAE June 3, UK MHRA June 11
Novo Nordisk's Wegovy pill (oral semaglutide tablets) went international in June. The Emirates Drug Establishment cleared the launch in the UAE on June 3, 2026, with pharmacies stocking all four dose strengths (1.5, 4, 9, 25 mg). The UK MHRA approved oral semaglutide 25 mg for chronic weight management on June 11 based on the Phase 3 OASIS 4 trial (13.6% weight loss at the 25 mg dose versus 2% on placebo). UK private-prescription availability is expected within weeks; NHS coverage requires a separate NICE cost-effectiveness appraisal. US prescription volume has crossed 3 million in the first five months since the January 5 launch.
| Channel | Price | Source |
|---|---|---|
| Wegovy Pill UAE (1.5 mg and 4 mg) | AED 779/mo (~$212 USD) | Khaleej Times |
| Wegovy Pill UAE (9 mg) | AED 1,199/mo (~$326 USD) | Khaleej Times |
| Wegovy Pill UAE (25 mg Maintenance) | AED 1,610/mo (~$438 USD) | The National (UAE) |
| Wegovy Pill UK (Private Prescription) | From £129/mo at launch (private) | Benzinga |
| Wegovy Pill UK NHS Access | TBD (NICE appraisal pending) | Simple Online Pharmacy |
Foundayo (Orforglipron) — Week 9 Tracker and CVS Caremark Open Coverage
Eli Lilly's oral GLP-1 pill, FDA-approved April 1, 2026 and launched April 7. The IQVIA tracker reported 16,982 prescriptions at Week 8; total patient count is higher because telehealth volume (around 35% of launch volume across 12+ platforms) is captured incompletely in retail-only data. With CVS Caremark removing the new-to-market block effective June 1, Foundayo now has formulary access across all three major US PBMs.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $649/mo | GoodRx |
| LillyDirect (Starting Dose) | $149/mo | Eli Lilly PR |
| LillyDirect (Maintenance Dose) | ~$349/mo | Drugs.com |
| Foundayo via Telehealth (Range) | $199-$399/mo | Fierce Pharma / Citi note |
| CVS Caremark Commercial | As low as $25/mo | CVS Health |
| TrumpRx (Oral GLP-1) | $150/mo | AMCP |
| Medicare Part D (Bridge) | $50/mo copay | KFF |
Wegovy Injectable — $199 Starter Promotion Closes June 30, Standard Tier Returns
Novo Nordisk's injectable semaglutide for chronic weight management. The promotional $199/month self-pay tier for 0.25 mg and 0.5 mg starter doses expires June 30, 2026, after which starter doses revert to the standard $349/month NovoCare self-pay tier. The 1.5 mg and 4 mg Wegovy pill doses are also at $149/month through August 31 before the 4 mg dose moves to $199. Wegovy HD 7.2 mg sits in its own $399/month self-pay tier. Wegovy injectable Q1 2026 sales hit DKK 12.7B (~$1.85B) on roughly 2.2 million Q1 prescriptions.
| Channel | Price | Source |
|---|---|---|
| List Price (WAC) | $1,349/mo | NovoCare |
| NovoCare Starter Promotion (0.25 + 0.5 mg) | $199/mo through June 30 | Wegovy.com |
| NovoCare Standard Self-Pay (1.0, 1.7, 2.4 mg) | $349/mo | Wegovy.com |
| NovoCare Self-Pay (Wegovy HD 7.2 mg) | $399/mo | Novo Nordisk PR |
| Commercial Insurance + Savings Card | As low as $25/mo | Wegovy.com |
| TrumpRx (Injectable GLP-1) | $346/mo starting | AJMC |
| Medicare Part D (Bridge) | $50/mo copay | CMS |
Zepbound (Tirzepatide) — LillyDirect Vials and CVS Caremark Return October 1
Eli Lilly's tirzepatide injection for chronic weight management. December 2025's LillyDirect vial pricing reduction (down to $299-$449/month from $349-$499) still holds. CVS Caremark's October 1 return as a preferred commercial-formulary option will be the largest US coverage shift for Zepbound this year. Mounjaro (same molecule, T2D indication) is covered by Caremark; the obesity indication has been the contested one.
| Channel | Price | Source |
|---|---|---|
| List Price (Prefilled Pens, Retail) | $1,000-$1,100/mo | GoodRx |
| LillyDirect Self-Pay Vials (2.5 mg) | $299/mo | PharmExec |
| LillyDirect Self-Pay Vials (5 mg) | $399/mo | PharmExec |
| LillyDirect Self-Pay Vials (7.5, 10, 12.5, 15 mg) | $449/mo | PharmExec |
| CVS Caremark Commercial | As low as $25/mo | CVS Health |
| TrumpRx (Injectable GLP-1) | $346/mo starting | AJMC |
| Medicare Part D (Bridge) | $50/mo copay | CMS |
Compounded Semaglutide & Tirzepatide — 16 Days to 503B Sunset
The FDA's April 30 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list opened a 60-day comment window that closes June 29, 2026, 16 days from today. After final rulemaking, large-scale compounding through 503B outsourcing facilities effectively ends. The 503A pathway through licensed pharmacies remains until the July 23-24 PCAC meeting. Telehealth platforms running on compounded supply (Hims & Hers, LifeMD, and others) have already migrated to branded distribution since Q1 2026. Patients currently on compounded versions will need to transition to branded supply via NovoCare, LillyDirect, PBM commercial coverage, or Medicare Bridge starting July 1.
| Channel | Price | Source |
|---|---|---|
| Compounded Semaglutide (Starting Dose) | $159-$199/mo | Newswire / Trinity Meds |
| Compounded Tirzepatide | $229-$349/mo | HealthFactsJournal |
| 503B Bulks List Removal (Comment Window) | Comment window closes June 29, 2026 | FDA |
| PCAC Oral-Presentation Deadline | June 30, 2026 | FDA |
| Hims & Hers Branded Pivot | Branded Wegovy/Ozempic via Novo partnership | Hims Investor Relations |
Medicare GLP-1 Bridge — 18 Days to Launch
The Medicare GLP-1 Bridge program launches July 1, 2026 with $50/month patient copay and a ~$245/month Medicare-negotiated price. Coverage runs through December 31, 2027. State Medicaid programs began joining May 1, 2026 and can opt in through January 1, 2027. Eligibility requires BMI 30+ with comorbidity, or BMI 27+ with pre-diabetes or established cardiovascular disease. Wegovy, Zepbound, and Foundayo are confirmed on the formulary. The April 22 cancellation of the broader BALANCE pilot constrained the program scope.